JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Building and Pilot Testing a Couples-based Smartphone Systems to Address Alcohol Use Disorder

  NCT04059549

  Conditions:   Alcohol Use Disorder;   Couples;   Behavior, Addictive
  Interventions:   Behavioral: PartnerCHESS;   Behavioral: A-CHESS
  Sponsors:   University of Wisconsin, Madison;   University of Massachusetts, Worcester
  Recruiting
• Transforming Recovery Through Exercise and Community

  NCT03065049

  Condition:   Opioid-use Disorder
  Interventions:   Behavioral: Peer-Facilitated Counseling;   Behavioral: Fitbit activity tracker
  Sponsors:   Butler Hospital;   National Institute on Drug Abuse (NIDA)
  Recruiting
• Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

  NCT03070899

  Conditions:   Uterine Fibroids;   Heavy Menstrual Bleeding
  Interventions:   Drug: Placebo + Placebo Add-back;   Drug: OBE2109 + Placebo Add-back;   Drug: OBE2109 + Add-back
  Sponsor:   ObsEva SA
  Recruiting
• A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain

  NCT03986944

  Condition:   Endometriosis
  Interventions:   Drug: Placebo linzagolix tablets and Placebo Add-back capsule;   Drug: Placebo linzagolix and linzagolix tablets and Placebo Add-back capsule;   Drug: Placebo linzagolix and linzagolix tablets and Add-back capsule
  Sponsor:   ObsEva SA
  Recruiting
• Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome

  NCT03951077

  Condition:   Polycystic Ovary Syndrome
  Interventions:   Drug: Elagolix;   Drug: Placebo
  Sponsor:   AbbVie
  Recruiting
• Project MIMIC (Maximizing Implementation of Motivational Incentives in Clinics)

  NCT03931174

  Condition:   Opioid-use Disorder
  Interventions:   Behavioral: Addiction Technology Transfer Center (ATTC) Training Strategy;   Behavioral: Enhanced Addiction Technology Transfer Center (E-ATTC) Training Strategy
  Sponsors:   Brown University;   RTI International;   University of Washington;   UConn Health
  Recruiting
• A Study in Patients With Moderate to Severe Active Crohn's Disease

  NCT03677648

  Condition:   Crohn's Disease
  Interventions:   Drug: SHR0302;   Drug: Placebos
  Sponsor:   Reistone Biopharma Company Limited
  Recruiting
• A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.

  NCT03675477

  Condition:   Ulcerative Colitis
  Interventions:   Drug: SHR0302;   Drug: Placebos
  Sponsor:   Reistone Biopharma Company Limited
  Recruiting
• A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

  NCT03987919

  Condition:   Type 2 Diabetes
  Interventions:   Drug: Tirzepatide;   Drug: Semaglutide
  Sponsor:   Eli Lilly and Company
  Recruiting
• Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD

  NCT03937479

  Condition:   COPD
  Interventions:   Drug: Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium;   Drug: Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium;   Drug: Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium;   Drug: Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium;   Drug: Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium
  Sponsors:   Verona Pharma plc;   Iqvia Pty Ltd;   LGC Limited
  Recruiting
• A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

  NCT03915964

  Condition:   Rheumatoid Arthritis
  Interventions:   Drug: Baricitinib;   Drug: TNF Inhibitor
  Sponsors:   Eli Lilly and Company;   Incyte Corporation
  Recruiting
• Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis

  NCT03890120

  Condition:   Primary Sclerosing Cholangitis
  Interventions:   Drug: Cilofexor;   Drug: Placebo
  Sponsor:   Gilead Sciences
  Recruiting
• A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

  NCT03736785

  Condition:   Type 2 Diabetes Mellitus
  Interventions:   Drug: LY3209590;   Drug: Insulin Degludec
  Sponsor:   Eli Lilly and Company
  Recruiting
• A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk

  NCT03730662

  Condition:   Type 2 Diabetes Mellitus
  Interventions:   Drug: Tirzepatide;   Drug: Insulin Glargine
  Sponsor:   Eli Lilly and Company
  Recruiting
• A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092

  Condition:   Ulcerative Colitis
  Interventions:   Drug: Mirikizumab;   Drug: Placebo
  Sponsor:   Eli Lilly and Company
  Recruiting
• An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086

  Condition:   Ulcerative Colitis
  Interventions:   Drug: Mirikizumab;   Drug: Placebo
  Sponsor:   Eli Lilly and Company
  Recruiting
• A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE )

  NCT03518034

  Conditions:   Hypogonadism;   Cardiovascular Diseases
  Interventions:   Drug: Testosterone;   Drug: Placebo
  Sponsors:   AbbVie;   Acerus Pharmaceuticals Corporation;   Allergan Sales, LLC;   Endo Pharmaceuticals;   Upsher-Smith Laboratories
  Recruiting
• A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

  NCT03486899

  Conditions:   Liver Fibrosis;   Nonalcoholic Fatty Liver Disease (NAFLD);   Nonalcoholic Steatohepatitis
  Interventions:   Drug: BMS-986036;   Other: Placebo
  Sponsor:   Bristol-Myers Squibb
  Recruiting
• Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma

  NCT03406078

  Condition:   Asthma
  Interventions:   Biological: Tezepelumab;   Other: Placebo
  Sponsors:   AstraZeneca;   Amgen
  Recruiting
• Strategic Management to Optimize Response To Cardiac Resynchronization Therapy

  NCT03089281

  Condition:   Heart Failure
  Intervention:   Device: CRT-D
  Sponsor:   Boston Scientific Corporation
  Recruiting
• Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency

  NCT03037931

  Conditions:   Heart Failure;   Iron-deficiency
  Interventions:   Drug: Ferric carboxymaltose;   Drug: Placebos
  Sponsors:   American Regent, Inc.;   Duke Clinical Research Institute
  Recruiting
• Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP

  NCT02923726

  Condition:   Sudden Cardiac Death
  Interventions:   Device: Arm 1 (ATP+Shock);   Device: Arm 2 (shock only)
  Sponsors:   Boston Scientific Corporation;   ICON plc
  Recruiting
• Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

  NCT03945188

  Condition:   Ulcerative Colitis
  Interventions:   Drug: Etrasimod;   Drug: Placebo
  Sponsor:   Arena Pharmaceuticals
  Recruiting
• Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

  NCT03893448

  Conditions:   Pneumococcal Infections;   Pneumococcal Vaccines
  Interventions:   Biological: V114;   Biological: Prevnar 13™;   Biological: RotaTeq™;   Biological: Pentacel™;   Biological: RECOMBIVAX HB™;   Biological: VAQTA™;   Biological: M-M-R™;   Biological: VARIVAX™;   Biological: HIBERIX™
  Sponsor:   Merck Sharp & Dohme Corp.
  Recruiting
• A Study of Oral VT-1161 for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

  NCT03562156

  Condition:   Recurrent Vulvovaginal Candidiasis
  Interventions:   Drug: VT-1161;   Drug: Placebo
  Sponsor:   Mycovia Pharmaceuticals Inc.
  Recruiting
• Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma

  NCT03347279

  Condition:   Asthma
  Interventions:   Biological: Experimental: Tezepelumab;   Other: Placebo
  Sponsors:   AstraZeneca;   Amgen
  Recruiting